International comparison of trends in patients commencing renal replacement therapy by primary renal disease

Vianda S. Stel*, Ryan Awadhpersad, Maria Pippias, Manuel Ferrer-Alamar, Patrik Finne, Simon D. Fraser, James G. Heaf, Marc H. Hemmelder, Alberto Martínez-Castelao, Johan de Meester, Runolfur Palsson, Friedrich C. Prischl, Mårten Segelmark, Jamie P. Traynor, Rafael Santamaria, Anna Varberg Reisæter, Ziad A. Massy, Kitty J. Jager

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


Aim: To examine international time trends in the incidence of renal replacement therapy (RRT) for end-stage renal disease (ESRD) by primary renal disease (PRD). Methods: Renal registries reporting on patients starting RRT per million population for ESRD by PRD from 2005 to 2014, were identified by internet search and literature review. The average annual percentage change (AAPC) with a 95% confidence interval (CI) of the time trends was computed using Joinpoint regression. Results: There was a significant decrease in the incidence of RRT for ESRD due to diabetes mellitus (DM) in Europe (AAPC = −0.9; 95%CI −1.3; −0.5) and to hypertension/renal vascular disease (HT/RVD) in Australia (AAPC = −1.8; 95%CI −3.3; −0.3), Canada (AAPC = −2.9; 95%CI −4.4; −1.5) and Europe (AAPC = −1.1; 95%CI −2.1; −0.0). A decrease or stabilization was observed for glomerulonephritis in all regions and for autosomal dominant polycystic kidney disease (ADPKD) in all regions except for Malaysia and the Republic of Korea. An increase of 5.2–16.3% was observed for DM, HT/RVD and ADPKD in Malaysia and the Republic of Korea. Conclusion: Large international differences exist in the trends in incidence of RRT by primary renal disease. Mapping of these international trends is the first step in defining the causes and successful preventative measures of CKD.

Sider (fra-til)1064-1076
Antal sider13
Udgave nummer10
StatusUdgivet - 1 okt. 2019


Udforsk hvilke forskningsemner 'International comparison of trends in patients commencing renal replacement therapy by primary renal disease' indeholder.